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ABSTRACT
D-phenylglycine-L-dopa, a dipeptide synthesized in this laboratory for improving the oral absorption of L-dopa, showed
better absorption and distribution in rats. We assumed that the extensive distribution might explain its sustained release of brain
dopamine. Since protein binding is a main factor of drug distribution, we investigated the effect of D-phenylglycine on the binding
of L-dopa to human serum albumin. The degree of the binding of D-phenylglycine, L-dopa and D-phenylglycine-L-dopa to serum
albumin was determined. Free and bound portion of test compounds were separated with ultrafiltration method and the assay of
free drug portion was conducted with reversed phase HPLC. The LOQ for D-phenylglycine, L-dopa and D-phenylglycine-L-dopa
was 0.5 μg/mL, 0.1 μg/mL and 0.5 μg/mL, respectively. Assay methods were validated by determining the precision and accuracy
of interday and intraday variations. The coefficient of variation (CV) was within 12% and the relative error (RE) was within 10%
(n = 3). The recovery rate was 95.4% - 98.1% for D-phenylglycine, 91.9 % - 98.8% for L-dopa and 96.8% - 97.9% for D-phenylglycine-L-dopa, respectively (n = 3). D-Phenylglycine showed higher serum albumin binding than L-dopa did at various concentrations. At a concentration of 600 μM, the degree of albumin binding of D-phenylglycine, L-dopa, D-phenylglycine-L-dopa was
27.98%, 8.20% and 19.18%, respectively. The albumin binding of L-dopa at this concentration increased by 2.4 folds when chemically bound to D-phenylglycine. The number of the binding sites of L-dopa increased by 5.8 folds and the binding constant Ka1
increased by 3.8 folds when L-dopa was chemically bound to D-phenylglycine. With the affinity to serum albumin, D-phenylglycine showed its possibility as a delivery moiety for drugs with limited distribution to use the body protein as a reservoir.
Key words: D-phenylglycine, L-dopa, D-phenylglycine-L-dopa, albumin, protein binding

INTRODUCTION
Studies indicated that orally absorbable aminoβ-lactams could enter the circulatory system through
the intestinal oligopeptide transporter, PepT1(1-7). As
D-Phenylglycine is a common moiety in molecules of
amino-β-lactams, we synthesized D-phenylglycine-Ldopa(8) to improve the low and inconsistent bioavailability
associated with L-dopa (9-14). This dipeptide showed 50
times higher plasma concentration than that of L-dopa
after intestinal perfusion in rats (8). Another study also
indicated that this dipeptide exhibited larger volume of
distribution and longer biological half-life than that of
L-dopa after oral administration in rats and in rabbits(8).
We assumed that the large volume of distribution might
explain its sustained release of brain dopamine. As
protein binding is one of the factors that affect drug
volume of distribution(15-17), it is interesting to investigate
if the protein binding of D-phenylglycine contributes
to the high volu me of dist r ibution associated with
D-phenylglycine-L-dopa. It would also be interesting
to understand if D-phenylglycine is feasible as a moiety
for designing sustained release prodrugs for drugs with
high clearance or poor pharmacokinetic profile. We
therefore designed a comparative protein binding assay on
D-phenylglycine, L-dopa and D-phenylglycine-L-dopa.
Studies were conducted in human serum albumin(18).
* Author for correspondence. Tel: +886-3-3273023;
Fax: +886-3-3273023 ; E-mail: hpw@mail.cgu.edu.tw

Free and protein-bound drug portions were separated
with ultrafiltration method (19-20). The analysis of free
drugs was conducted with reversed phase HPLC. Assay
methods were validated by determining the precision
and accuracy of interday and intraday variations. The
recover y of d r ugs was deter mined. The deg ree of
serum albumin binding of D-phenylglycine, L-dopa and
D-phenylglycine-L-dopa were compared. The binding
kinetics was also investigated(21-23).

MATERIALS AND METHODS
I. Materials
D-Phenylglycine-L-dopa was synthesized in this
laboratory (8). D-(-)-α-Phenylglycine and L-dopa were
purchased from Acros Organics (New Jersey, USA).
Human albumin was purchased from Sigma Chemical
(Stein heim, Ger meny). Sodium chlor ide was f rom
Riedel-de Haen (Seelze, Germany). Ortho-phosphoric
acid 85%, potassium dihydrogen phosphate, di-Sodium
hydrogen phosphate and acetonitrile were from Merck
(Darmstadt, Germany). Sodium hydroxide was from
Riedel-de Haen (Seelze, Germany). Branson Sonifier
450 sonicator, Kubota 2010, Eppendorf 5415C centrifuge,
Model 905 incubator (Cher ng Huei Instr ument Co.)
and Ystral Laboratory series x10/20 Homogenizer were
used for the preparation of test solutions. Osmolarity of
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test solutions was determined with Wescor 5500 vapor
pressure osmometer (Wescor Company, Logan, UT, USA).
Samples after incubation were vortexed in a Scientific
Industries Vortex Genie2 (Bohemia, USA), centrifuged
with Hettich Mikro 22R (Tuttlingen, Germany), and
f ilt e re d w it h M il l ipore A m icon M ic rocon Y M-30
Centrifugal Filter Units (Bedford, USA).
II. Test Solutions
Isotonic Sorensen phosphate buffer solution was
pre pa red by a dd i ng pot a ssiu m d i hyd rophosphor ic
acid (1.78 g), disodium hydrophosphoric acid (7.61 g)
and sodium chloride (9.00 g) in deionized water (1000
mL) and adjusted to pH 7.4 by 3N sodium hydroxide
solution. Isotonic human serum albumin solution was
prepared by adding 10 mg of human serum albumin in
125 μL of Sorensen phosphate buffer solution. Stock
solutions of test drugs was prepared by adding 10 mg of
test compounds in 10 mL of Sorensen phosphate buffer
and adjusted to 1000 μg/mL. Stock test solutions were
prepared by serial dilution of the stock solutions (1000 μg/
mL) with Sorensen phosphate buffer.
III. Chromatography
Samples were assayed in a HPLC system consisting
of a Jasco PU-1580 pu mp (Tok yo, Japa n), a Jasco
UV-1575 detector (Tokyo, Japan), a Jasco AS-1555-10
autosampler (Tokyo, Japan), and a Jasco Borwin integretor
(Tokyo, Japan). Samples were analyzed with a Merck
LiChrospher 100 RP-18e reversed-phase column (5 μm,
250×4 mm, Darmstadt, Germany). D-Phenylglycine and
L-dopa were eluted at a f low rate of 1.0 mL/min with
0.1 M phosphate buffer solution adjusted to pH 2.0 with
ammonium hydroxide solution, and detected by UV at
236 nm of wavelength. D-Phenylglycine and L-dopa
(50 μg/mL) were used as each other’s internal standard.
D-Phenylglycine-L-dopa, by adding acetanilide as the
internal standard, was eluted at a flow rate of 1.2 mL/min
with a solvent system comprising acetonitrile and water
at a ratio of 85:15 and was detected by UV at 197 nm of
wavelength.
IV. Validation of Assay Methods
HPLC assay methods were validated by determining
the precision and accuracy of intraday and interday
analysis of serum standards over a period of 6 days. The
limit of detection (LOD) and the limit of quantitation
(LOQ) were determined to establish the standard curve
for HPLC assay. Recover y of test subject was also
determined.
V. Protein Binding Assay
Ult raf ilt ration method was adopted for protein

binding assay. In order to measure the drug binding on
the filtering membrane, drug solutions (500 μL of 0.1
μg/mL, 1 μg/mL, 10 μg/mL and 100 μg/mL) were first
placed in a Microcon YM-30 filter, of which particles with
molecular weight lower than 30,000 dalton were filtered,
and centrifuged at 5312 g for 10 minutes. The filtrates
were then subjected to HPLC assay.
Drug solutions (250 μL of 0.1 μg/mL, 1 μg/mL, 10
μg/mL and 100 μg/mL) were incubation with 250 μL of
human serum albumin (1.23×10 -3 M, 8%) at 37°C for 5
minutes and then diluted to a final solution with human
serum albumin at a concentration of 6.15×10 -4 M (4%).
The solutions were then vortexed and incubated at 37°
C for 10 minutes. Afterwards, the test solutions (230
μL) were then placed in a Microcon YM-30 filter and
centrifuged at 531 g for 10 minutes. The filtrates were
diluted and subjected to HPLC assay.
VI. Data Analysis
Data analysis was perfor med on Visual d Base
and SPSS/PC + and was presented as mean±S.D. of n
experiments. Differences were evaluated by one-way
ANOVA (p < 0.05). Parameters of albumin binding
kinetics were derived by establishing the r/[D] vs r
Scatchard plot. One binding-site model (equation 1),
two binding-site model (equation 2), and one nonspecific
bi nd i ng model (e qu at ion 3) we re a dopt e d for t he
calculation of the parameters, where r represents moles
of bound drug per mole of protein, Ka1 and Ka 2 represent
binding constants (L/mol), [D] represents free dr ug
concentration, and n represents the number of dr ug
binding sites (sites/L)(24).
r=

nKa[D]
1 + Ka[D]

(1)

r=

n1Ka1[D]
n2Ka2[D]
+
1 + Ka1[D] 1 + Ka2[D]

(2)

n1Ka1[D]
r = 1 + Ka [D] + Ka 2[D]
1

(3)

RESULTS AND DISCUSSION
D-phenylglycine, L-dopa and D-phenylglycine-Ldopa were assayed with HPLC. The retention time of
D-phenylglycine, L-dopa and D-phenylglycine-L-dopa
was 6.1, 10.6 and 4.9 min, respectively.
T he limit of detection (LOD) and the limit of
quantitation (LOQ) for D-phenylglycine was 0.05 μg/mL
and 0.5 g/mL, respectively. It demonstrated good linearity
at concentration range between 0.1 ~ 100 μg/mL (0.66 ~
661.55 μM) in intraday assays (regression coefficient (r)
> 0.9998, n = 3, relative error (R. E.) +0.49 ~ +4.97%,
coefficient of variation (C. V.) < 12%) and interday assays
(r > 0.9997, R. E. +0.61 ~ +9.82 %, C. V. < 10%) assays.
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Table 1. The degree of protein binding of D-Phenylglycine, L-Dopa and D-Phenylglycine-L-dopa.
D-Phenylglycine

L-Dopa

D-Phenylglycine-L-dopa

Concentration of test
drug (μg/mL)

Concentration of
bound drugs (μg/mL)

%
binding

Concentration of
bound drugs (μg/mL)

%
binding

Concentration of
bound drugs (μg/mL)

%
binding

1

0.31 ± 0.05

30.67

0.10 ± 0.03

10.00

0.22 ± 0.03

22.33

5

1.56 ± 0.06

31.27

0.56 ± 0.06

11.13

1.20 ± 0.10

23.93

10

2.98 ± 0.12

29.80

0.90 ± 0.16

9.03

2.32 ± 0.07

23.20

30

9.55 ± 1.48

31.84

2.41 ± 0.74

8.03

5.45 ± 0.64

18.17

50

14.05 ± 1.47

28.09

4.98 ± 1.91

9.95

9.60 ± 0.64

19.19

100

25.97 ± 4.21

25.90

7.62 ± 1.44

7.62

18.22 ± 1.34

18.22

300

71.10 ± 6.27

23.70

20.35 ± 5.25

6.78

52.18 ± 9.24

17.39

500

121.83 ± 7.46

24.37

26.49 ± 6.91

5.30

77.98 ± 13.79

15.60

1000

198.54 ± 15.06

19.85

36.35 ± 8.38

3.64

106.54 ± 17.76

10.65

2000

332.72 ± 65.29

16.64

79.86 ± 25.85

3.99

216.29 ± 52.51

10.81

Table 2. D-Phenylglycine, when chemically bound to L-dopa, increased the degree of protein-binding of L-dopa.
Compound

Molecular weight

concentration equivalent to
600 μM (μg/mL)

Degree of
albumin binding* (%)

ratio
3.4**

D-Phenylglycine

151.2

90.72

27.98

L-Dopa

197.2

118.32

8.20

D-Phenylglycine-L-dopa

330.3

198.18

19.18

1.0
2.4**

*The degree of albumin binding was derived via regression analysis from the data of Table 1.
**One Way ANOVA, p < 0.05.

450.00

Concentration of bound compound
(µg/mL)

The recovery rate for D-phenylglycine was between 95.4%
- 98.1% (n = 3).
The LOD and LOQ for L-dopa was 0.01 μg/mL and
0.1 μg/mL, respectively. Good linearity was demonstrated
at concentration range of 0.1 ~ 100 μg/mL (0.51 ~ 507.13
μM) in intraday assays (r > 0.9998, n = 3, R. E. +0.46 ~
+9.27%, C. V. <10%) and interday assays (r> 0.9995 R. E.
+0.76 ~ +8.17%, C. V. < 7.2%) assays. The recovery rate
was between 91.9 % - 98.8% (n = 3).
The LOD and LOQ for D-phenylglycine-L-dopa was
0.05 μg/mL and 0.5 μg/mL respectively. Good linearity
at concentration range between 0.1 ~ 100 μg/mL (0.30 ~
303.63 μM) in intraday assays (r > 0.9996, n = 3, R. E.
+0.76 ~ +8.37%, C. V. < 5%) and interday assays (r > 0.9992
R. E. +0.91 ~ +9.06%, C. V. < 6.1%) were demonstrated.
T he recover y rate of D -phenylglyci ne-L - dopa was
between 96.8% - 97.9% (n = 3).
The concent ration of the bou nd por tion to the
concentration of total test compound was analyzed. Dose
dependent binding at concentration range of 0-2000
μg/mL was observed for D-phenylglycine, L-dopa and
D-phenylglycine-L-dopa (Figure 1). The degrees of
albumin binding between D-phenylglycine, L-dopa and
D-phenylglycine-L-dopa were compared (Table 1). Both
D-phenylglycine-L-dopa and D-phenylglycine showed
higher binding to human serum albumin than L-dopa at
various concentrations. At concentration of 600 μM, for
example, the bound portion of D-phenylglycine, L-dopa

D-Phenylglycine
D-Phenylglycine-L-dopa
L-Dopa

400.00
350.00
300.00
250.00
200.00
150.00
100.00
50.00
0.00

0

500

1000

1500

2000

2500

Concentration of test compound (µg/mL)

Fig ure 1. Compa r ison of ser u m albu m i n bi nd i ng of
D-phenylglycine, L-dopa and D-phenylglycine-L-dopa.

and D-phenylglycine-L-dopa to ser um albumin was
27.98%, 8.20% and 19.18%, respectively. The albumin
binding of D-phenylglycine was 3.4 times stronger than
that of L-dopa. The albumin binding of L-dopa, when
chemically bound to D-phenylglycine, increased by 2.4
folds at this concentration (Table 2).
The kinetics of serum albumin binding of the three
compounds was also investigated, and the Scatchard’s plot
of r/[D] vs r was established (Figure. 2). The parameters
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were calculated according to the one binding-site model,
two binding-site model and non-specific binding model(24).
A kaike’s infor mation cr iter ion (AIC) was used for
evaluation and for the selection of the best fit model(25).
As judged by AIC, D-phenylglycine exhibited higher
possibility of two binding-site interaction with serum
albumin than L-dopa and the dipeptide D-phenylglycineL-dopa. In the D-phenylglycine case, the Ka1 calculated
from two binding-site model was larger than the Ka1

calculated from one binding-site model (0.56 vs 0.11),
indicating a possibility of allosteric induction when
D-phenylglycine is bound to serum albumin. Based on the
data calculated from one binding-site model, the binding
constant (Ka1) of D-phenylglycine was lower than that of
L-dopa (0.11 vs 0.30) (Table 3). However, its binding site
(n, sites/L) was 10 times more to that of L-dopa (6.00 vs
0.59). When D-phenylglycine was chemically bound to
L-dopa, the binding sites (n, sites/L) of the dipeptide to

Table 3. The kinetic parameters of the binding of D-Phenylglycine, L-Dopa and D-Phenylglycine-L-dopa to human serum albumin
calculated based on Scatchard plot.
D-Phenylglycine

L-Dopa

D-Phenylglycine-L-dopa

6.00

0.59

3.41

One binding-site model
n (sites/L)
Ka1 (L/mol)

0.11

0.30

1.13

32.92

0.17

23.06

n1 (sites/L)

1.32

1.09

0.39

Ka1 (L/mol)

0.56

0.15

1.28

n2 (sites/L)

8.01

1.91

4.38

AIC
Two binding-site model

Ka2 (L/mol)
AIC

0.07

0.06

0.08

20.16

43.19

34.58

2.73

0.91

2.01

non-specific binding
n (sites/L)
Ka1 (L/mol)

0.39

0.20

0.82

Ka2 (L/mol)

0.34

0.07

0.20

28.51

46.06

38.92

AIC

0.8

Scatchard plot

(a)

0.6

0.7

0.5

0.6

0.4

r/D

r/D

0.5
0.4

(c)

Scatchard plot

0.3
0.2

0.3
0.2

0.1

0.1

0.0
0.0

0.0
0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

0.5

1.0

r

1.5

2.0

2.5

r
0.25

(b)

Scatchard plot

r/D

0.20
0.15
0.10
0.05
0.00
0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

r

Figure 2. Scatchard plot of the binding of (a) D-phenylglycine (n = 3), (b) L-dopa (n = 3) and (c) D-phenylglycine- L-dopa (n = 3) to human
serum albumin. r denotes moles of test compound bound to albumin per mole of protein. D denotes free drug concentration.
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serum albumin increased by 5.8 folds (3.41 vs 0.59) and
the Ka1 increased by 3.8 folds (1.13 vs 0.30).

CONCLUSIONS
This st udy demonst rated that D -phenylglycine
i ncrea sed t he bi nd i ng of L - dopa to hu ma n ser u m
albumin. In comparison to L-dopa, the higher affinity
of D-phenylglycine-L-dopa to albumin came from both
an increased binding constant and the number of binding
sites. With the affinity of D-phenylglycine to serum
albumin, this moiety showed its possibility as a delivery
tool for drugs with high clearance and short biological
half life to use the body protein as drug reservoir.
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